Vaccine最新文献

{"title":"Corrigendum to “Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection” [Vaccine 42 (1–12) (2024) 126325]","authors":"Susan D. Kerfua , Daniel T. Haydon , Ginette Wilsden , Anna Ludi , Donald P. King , Rose Ademun Okurut , Stella Atim , Moses T. Dhikusooka , Ivan Kyakuwa , Paolo Motta , David J. Paton","doi":"10.1016/j.vaccine.2024.126480","DOIUrl":"10.1016/j.vaccine.2024.126480","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126480"},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost effectiveness analysis of rotavirus vaccination in Indonesia","authors":"Jarir At Thobari ,&nbsp;Emma Watts ,&nbsp;Natalie Carvalho ,&nbsp;Jonathan Hasian Haposan ,&nbsp;Andrew Clark ,&nbsp;Frédéric Debellut ,&nbsp;Asal Wahyuni Erlin Mulyadi ,&nbsp;Julitasari Sundoro ,&nbsp;Mardiati Nadjib ,&nbsp;Sri Redzeki Hadinegoro ,&nbsp;Julie Bines ,&nbsp;Yati Soenarto","doi":"10.1016/j.vaccine.2024.126478","DOIUrl":"10.1016/j.vaccine.2024.126478","url":null,"abstract":"<div><h3>Background</h3><div>Rotavirus (RV) remains the most common cause of morbidity and mortality due to acute gastroenteritis (AGE) in children under five. In Indonesia, RV is responsible for 60 % of severe AGE and 40 % of non-severe AGE in these children. This study assessed the cost-effectiveness of introduction of rotavirus vaccines (RVV) into the National Immunization Program in Indonesia.</div></div><div><h3>Methods</h3><div>We conducted a cost-effectiveness analysis (CEA) of RVV introduction in Indonesia, assuming a three-dose vaccine schedule based on the planned introduction proposed by the Strategic Advisory Group of Experts on Immunization. The analysis involved an initial introduction of an imported RVV (Rotavac®, Bharat Biotech, India) followed by a staged implementation of the locally produced RVV (Bio Farma, Indonesia) from both health system and societal perspectives. The primary outcome measure was the incremental cost (2019 USD) per disability-adjusted life year (DALY) averted, compared to no vaccination. We took model inputs from an Indonesian cost-of-illness study, national information systems and scientific literature, covering disease incidence, hospitalization, mortality, healthcare costs, and vaccine related factors. Our analyses included univariate and probabilitistic sensitivity analyses to assess various parameters.</div></div><div><h3>Findings</h3><div>The cost of a 10-year vaccination program is 82.6 million USD and can potentially prevent 7.3 million cases of rotavirus and 0.42 million DALYs. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the staged program is 464 USD per DALY averted (12 % of Indonesia's gross domestic product (GDP) per capita). From a healthcare sector perspective, ICER is similar at 479 USD (13 % GDP per capita).</div></div><div><h3>Interpretation</h3><div>The introduction of RVV into the National Immunization Program is likely to be highly cost-effective in Indonesia.</div></div><div><h3>Funding</h3><div>This work was supported by funding agreement with the Murdoch Children's Research Institute (MCRI), PATH, and the Indonesian Technical Advisory Group on Immunization (ITAGI).</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126478"},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis","authors":"Oghenebrume Wariri ,&nbsp;Chigozie Edson Utazi ,&nbsp;Uduak Okomo ,&nbsp;Winfred Dotse-Gborgbortsi ,&nbsp;Malick Sogur ,&nbsp;Sidat Fofana ,&nbsp;Kris A. Murray ,&nbsp;Chris Grundy ,&nbsp;Beate Kampmann","doi":"10.1016/j.vaccine.2024.126500","DOIUrl":"10.1016/j.vaccine.2024.126500","url":null,"abstract":"<div><h3>Introduction</h3><div>Achieving the ambitious goals of the Immunisation Agenda 2030 (IA2030) requires a deeper understanding of factors influencing under-vaccination, including timely vaccination. This study investigates the demand- and supply-side determinants influencing the timely uptake of key childhood vaccines scheduled throughout the first year of life in The Gambia.</div></div><div><h3>Methods</h3><div>We used two nationally-representative datasets: the 2019–20 Gambian Demographic and Health Survey and the 2019 national immunisation facility mapping. Using Bayesian multi-level binary logistic regression models, we identified key factors significantly associated with timely vaccination for five key vaccines: birth dose of hepatitis-B (HepB0), first, second, and third doses of the pentavalent vaccine (Penta1, Penta2, Penta3), and first-dose of measles-containing vaccine (MCV1) in children aged 12–35 months. We report the adjusted Odds Ratios (aORs) and 95 % Credible Intervals (95 % CIs) in each case.</div></div><div><h3>Results</h3><div>We found that demand-side factors, such as ethnicity, household wealth status, maternal education, maternal parity, and the duration of the household's residency in its current location, were the most common drivers of timely childhood vaccination. However, supply-side factors such as travel time to the nearest immunisation clinic, availability of cold-storage and staffing numbers in the nearest immunisation clinic were also significant determinants. Furthermore, the determinants varied across specific vaccines and the timing of doses. For example, delivery in a health facility (aOR = 1.58, 95 %CI: 1.02–2.53), living less than 30 min (aOR = 2.11, 95 %CI: 1.2–8.84) and living between 30 and 60 min (aOR = 3.68, 95 %CI: 1.1–14.99) from a fixed-immunisation clinic was associated with timely HepB0, a time-sensitive vaccine that must be administered within 24 h of birth. On the other hand, children who received Penta1 and Penta2 on time were three- to five-fold more likely to receive subsequent doses on time (Penta2 and Penta3, respectively). Finally, proximity to an immunisation facility with functional vaccine cold-storage was a significant supply-side determinant of timely MCV1 (aOR = 1.4, 95 %CI: 1.09–1.99).</div></div><div><h3>Conclusions</h3><div>These findings provide valuable insights for programme managers and policymakers. By prioritising interventions and allocating scarce resources based on these identified determinants, they can maximize their impact and ensure children in The Gambia receive timely vaccinations throughout their first year of life, contributing to IA2030 goals.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126500"},"PeriodicalIF":4.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada","authors":"Katia Charland ,&nbsp;Caroline Quach ,&nbsp;Jesse Papenburg ,&nbsp;Laura Pierce ,&nbsp;Cat Tuong Nguyen ,&nbsp;Adrien Saucier ,&nbsp;Margot Barbosa Da Torre ,&nbsp;Marie-Ève Hamelin ,&nbsp;Julie Carbonneau ,&nbsp;Guy Boivin ,&nbsp;Kate Zinszer","doi":"10.1016/j.vaccine.2024.126489","DOIUrl":"10.1016/j.vaccine.2024.126489","url":null,"abstract":"<div><h3>Background</h3><div>Given the growing evidence on the benefits of hybrid immunity, continued monitoring of vaccine uptake is warranted, particularly of socio-demographic subgroups with early vaccine hesitancy. Racial/ethnic and lower income groups experienced a high infection incidence, but few studies account for the child's history of SARS-CoV-2 infection on the parent's decision to vaccinate their child.</div></div><div><h3>Methods</h3><div>EnCORE is a SARS-CoV-2 pediatric cohort study comprising five rounds of data collection from 2020 to 2023, with parental questionnaires at each round. Parent's responses on their intention to vaccinate their child and their reasons were summarized descriptively. Vaccine uptake was estimated through time and in relation to participant characteristics, using multivariable regression to adjust for covariates including a history of PCR/serology-confirmed SARS-CoV-2 infection prior to vaccine eligibility. At study end, we estimated the average time lapsed from last vaccine dose.</div></div><div><h3>Results</h3><div>The samples for vaccine uptake and intention to vaccinate analyses were 631 and 1137 participants, respectively. At study end, uptake was 88 % but approximately 49 % of 2-to-4-year-olds remained unvaccinated (95 % CI 39.0, 58.1) and for vaccinated participants the median time since last vaccination was 353 days. In regression analyses, after adjusting for infection prior to vaccine eligibility and other covariates, we found approximately a two-fold increase in unvaccinated status associated with the parent's identification as a racial/ethnic minority and with household income in the lowest sample tercile (minority: adjusted relative risk [aRR] 2.45, 95 % CI 1.56, 3.86; income: aRR 1.76, 95 % CI 1.17, 2.66).</div></div><div><h3>Conclusion</h3><div>By mid-2023, most participants were not protected by vaccine-induced antibodies, because they were unvaccinated or several months had lapsed from their last dose. A COVID-19 infection prior to vaccine eligibility was associated with a greater risk of remaining unvaccinated but did not fully account for low uptake in ethnic/racial minorities and lower income groups.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126489"},"PeriodicalIF":4.5,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Lassa fever disease in pregnant women and children and options for prevention","authors":"Manu Chaudhary ,&nbsp;Clare L. Cutland ,&nbsp;Mercedes Bonet ,&nbsp;Angela Gentile ,&nbsp;Christine E. Jones ,&nbsp;Helen S. Marshall ,&nbsp;Andy Stergachis ,&nbsp;Gerald Voss ,&nbsp;Delese Mimi Darko ,&nbsp;Esperanca Sevene ,&nbsp;Terri Hyde ,&nbsp;Lee Fairlie ,&nbsp;Beate Kampmann ,&nbsp;Darcie Everett ,&nbsp;Flor M. Munoz","doi":"10.1016/j.vaccine.2024.126479","DOIUrl":"10.1016/j.vaccine.2024.126479","url":null,"abstract":"<div><div>Lassa fever is a serious epidemic viral disease in West Africa affecting an estimated 2 million people annually with about 5000–10,000 deaths, although supporting data is sparse. Lassa fever significantly affects neonates, children, and pregnant women, however, comprehensive data on its impact in these populations are lacking. We reviewed the available literature on Lassa fever to assess its prevalence and impact in these populations and implications for vaccine development. Clinical features in children were similar to those observed in adults, with complications such as bleeding. Altered mental status, anasarca (swollen baby syndrome), bleeding, and poor urine output were risk factors for death. The case fatality rate (CFR) in 16 paediatric studies ranged from 6 % to 63 % and was 66.7 % and 75.0 % in two neonatal studies. In a systematic review of studies on pregnant women the CFR was 33.73 %. The adverse foetal outcomes included miscarriage, stillbirth, and intrauterine death associated with maternal death. Since Lassa fever significantly affects neonates, children, and pregnant women, developing a safe and effective, single-dose vaccine for these high-risk populations is vital. Currently, there are four clinical trials assessing Lassa virus vaccines. Only one of these trials is enrolling children aged ≥18 months, and exclude pregnant and breast-feeding women. It is essential that pregnant and breast-feeding women and young children are included in clinical trials that incorporate robust safety surveillance and risk mitigation measures. In our review, potential approaches to address the specific gaps in the areas of diagnosis, management, and prevention of Lassa fever in these specific populations, such as disease surveillance systems and vaccine development, were identified. A comprehensive strategy with investment focused on addressing specific knowledge gaps will be essential in protecting the health of these specific populations in Lassa virus endemic regions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126479"},"PeriodicalIF":4.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses","authors":"Aleda M. Leis ,&nbsp;Abram Wagner ,&nbsp;Brendan Flannery ,&nbsp;Jessie R. Chung ,&nbsp;Arnold S. Monto ,&nbsp;Emily T. Martin","doi":"10.1016/j.vaccine.2024.126493","DOIUrl":"10.1016/j.vaccine.2024.126493","url":null,"abstract":"<div><div>Test-negative design (TND) studies are cornerstones of vaccine effectiveness (VE) monitoring for influenza. The introduction of SARS-CoV-2 and RSV vaccines complicate the analysis of this design, with control selection restriction based on other pathogen diagnosis proposed as a solution. We conducted a simulation study and secondary analysis of 2017–18 and 2018–19 TND estimates from a Southeast Michigan ambulatory population to evaluate RSV-status-based control restriction. Simulations suggest that with vaccine-preventable RSV, influenza VE could be moderately biased with RSV prevalence ≥25 % of controls. Real-world analysis showed 151 influenza-negative adults (10.4 %) had RSV detected from the enrollment nasal swab. There were minimal differences in results of adjusted models with or without RSV exclusion from control groups. Findings suggest that inclusion of RSV cases in the control group of TND studies for influenza VE, particularly where RSV is not vaccine preventable, does not currently pose a major concern for bias in VE estimates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126493"},"PeriodicalIF":4.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.","authors":"Reuben McGregor ,&nbsp;Aimee Paterson ,&nbsp;Brittany Lavender ,&nbsp;Caitlin Hooker ,&nbsp;Chris Frampton ,&nbsp;Kjesten Wiig ,&nbsp;Graham Le Gros ,&nbsp;James E. Ussher ,&nbsp;Maia Brewerton ,&nbsp;Nicole J. Moreland","doi":"10.1016/j.vaccine.2024.126482","DOIUrl":"10.1016/j.vaccine.2024.126482","url":null,"abstract":"<div><div>The successive dominance of SARS-CoV-2 omicron sublineages presents challenges for vaccination strategies with respect to the antigenic content of boosters. New Zealand's COVID-19 elimination strategy (2020−2021) ensured the major vaccination campaign (Pfizer-BioNTech BNT162b2) was completed pre-omicron in an infection-naive population, providing a unique setting to explore the impact of omicron infection waves on vaccine responses. This study compared neutralising antibodies (NAb) to eight SARS-CoV-2 omicron sublineages 28-days and 11-months after a third dose. Participants (<em>n</em> = 219) were classified by antigen exposure in the intervening 10 months including additional vaccinations and/or infections. Both vaccination and infection boosted NAb levels to all sublineages. Antigenic maps showed infection had a major impact on NAb breadth, despite all participants being vaccinated with an ancestral-based vaccine.</div><div>While vaccination remains an important tool to boost immunity, the breadth of NAbs observed suggest that attempts to match booster specificity with current circulating variants may not always be necessary.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126482"},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review","authors":"Eleftheria Lentakis ,&nbsp;Holly Seale ,&nbsp;Rajeka Lazarus ,&nbsp;Sandra Mounier-Jack","doi":"10.1016/j.vaccine.2024.126472","DOIUrl":"10.1016/j.vaccine.2024.126472","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;There are several identified service user and provider barriers which lead to missed vaccination opportunities for adults within primary care. Programs delivering vaccination in non-primary care settings, such as in emergency departments, hospitals, specialist clinic and non-medical settings may assist in filling these gaps, especially among under-served populations. While expanding the locations in which vaccines are provided may improve uptake, there is a need to explore service user and provider attitudes towards delivery.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This scoping review aims to explore perceptions and attitudes of adult service users and providers towards receiving and delivering vaccination in non-primary care settings and identify how attitudes relate to determinants of vaccine compliance.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This scoping review was conducted in accordance with Joanna Briggs Institute (JBI) guidance for scoping reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Studies that focused on attitudes and perceptions of adult service users and providers towards the delivery of influenza, COVID-19, pneumococcal, and herpes zoster vaccines in non-primary care settings were included. Primary, peer-reviewed studies published in English from 01/01/2010 to 31/12/2023 were sought. Studies that focused on vaccination in primary care settings, the operational delivery of vaccination programs and interventions, children or adolescents less than 18 years, pregnant women, and healthcare workers receiving vaccination for occupational purposes were excluded.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;30 studies were included for final analysis in this study. 22 were cross-sectional studies, and 19 were published in the United States. 15 studies were conducted in non-medical settings and 11 in the emergency department. Findings showed that service users were receptive towards vaccination in non-primary care settings and were especially motivated by the convenience of non-medical settings such as workplaces, mobile clinics, drive through clinics, and faith-based organisations. A number of service user barriers were reported to vaccine acceptance, including low confidence in vaccines, fear of adverse effects, and low risk perception of infection. Findings of the included studies highlight a number of provider attitudinal barriers to the delivery of vaccinations outside of primary care, such as considering the process too time-consuming, costly, and detracting from the purpose of their work, although the number of studies assessing provider attitudes were limited.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Overall, there is a limited amount of evidence available regarding the attitudes to vaccination in non-primary care settings, especially among providers. There is a need for more study in this area to strengthen understanding of attitudes to","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126472"},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chikungunya vaccine development, challenges, and pathway toward public health impact","authors":"Clara Maure ,&nbsp;Kanat Khazhidinov ,&nbsp;Hyolim Kang ,&nbsp;Megan Auzenbergs ,&nbsp;Pascaline Moyersoen ,&nbsp;Kaja Abbas ,&nbsp;Gustavo Mendes Lima Santos ,&nbsp;Libia Milena Hernandez Medina ,&nbsp;T. Anh Wartel ,&nbsp;Jerome H. Kim ,&nbsp;John Clemens ,&nbsp;Sushant Sahastrabuddhe","doi":"10.1016/j.vaccine.2024.126483","DOIUrl":"10.1016/j.vaccine.2024.126483","url":null,"abstract":"<div><div>Chikungunya is a neglected tropical disease of growing public health concern with outbreaks in more than 114 countries in Asia, Africa, Americas, Europe, and Oceania since 2004. There are no specific antiviral treatment options for chikungunya virus infection. This article describes the chikungunya vaccine pipeline and assesses the challenges in the path to licensure, access, and uptake of chikungunya vaccines in populations at risk. Ixchiq (VLA1533/Ixchiq – Valneva) was the first licensed chikungunya vaccine by the US Food and Drug Administration in November 2023, European Medicines Agency in May 2024, and Health Canada in June 2024. Five chikungunya vaccine candidates (BBV87 – BBIL/IVI, MV-CHIK – Themis Bioscience, ChAdOx1 Chik – University of Oxford, PXVX0317 / VRC-CHKVLP059–00-VP – Bavarian Nordic, and mRNA-1388 – Moderna) are in development. Evidence on chikungunya disease burden alongside the public health and economic impact of vaccination are critical for decision-making on chikungunya vaccine introduction in endemic and epidemic settings. Further, global and regional stakeholders need to agree on a sustainable financing mechanism for manufacturing at scale to facilitate fair access and equitable vaccine distribution to at-risk populations in different geographic settings. This could partly be facilitated through obtaining consensus on scientific and regulatory principles for initial vaccine introduction and generating evidence on chikungunya burden and disease awareness among populations at risk. Specifically, this article advocates for the formation of a global chikungunya vaccine consortium that includes regulators, policymakers, sponsors, and manufacturers to assist in overcoming the global and local challenges for chikungunya vaccine licensure, policy, financing, demand generation, and access to at-risk populations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126483"},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review","authors":"Eleftheria Lentakis ,&nbsp;Holly Seale ,&nbsp;Rajeka Lazarus ,&nbsp;Sandra Mounier-Jack","doi":"10.1016/j.vaccine.2024.126458","DOIUrl":"10.1016/j.vaccine.2024.126458","url":null,"abstract":"<div><h3>Background</h3><div>There are several identified barriers to immunisation delivery and uptake in adults, including governance issues, provider limitations, and patient access. While primary care settings have traditionally been responsible for vaccine delivery, there is a growing need to look to other settings to expand the equitable uptake of vaccinations in adults.</div></div><div><h3>Objectives</h3><div>This scoping review aims to identify and explore the role of non-primary care settings in delivering adult vaccinations, operational barriers and facilitators to immunisation delivery in these settings, and interventions delivered to improve uptake.</div></div><div><h3>Methods</h3><div>This scoping review was conducted following the Joanna Briggs Institute (JBI) guidance for scoping reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Peer-reviewed studies published from 01/01/2010 to 31/12/2022 that focused on the delivery of influenza, COVID-19, pneumococcal and herpes zoster vaccines in adult populations outside of primary care settings were included. Studies were also included if they explored barriers and facilitators to delivery, and interventions to improve uptake.</div></div><div><h3>Results</h3><div>75 studies were identified for inclusion. Most were quasi-experimental studies, and 58/75 were from the US. Studies were most frequently conducted in in-patient settings, outpatient clinics, nursing homes, and workplaces. Operational planning and logistics, and provider-level issues, such as poor documentation and workflow interruption were commonly identified barriers to delivery. Government funding, continuity of care, and patient convenience were frequently reported facilitators. Interventions shown to improve uptake were operational planning and clinical improvement systems (Plan-Do-Study-Act [PDSA] cycles), provider education and reminders, on-site vaccination, patient education, and financial incentives.</div></div><div><h3>Conclusions</h3><div>Mapping of the evidence indicates that adult immunisation delivery may be achievable across tertiary and secondary care settings, as well as non-clinical settings, such as workplaces. There are several identified barriers to delivery, predominantly at the provider-level in tertiary-care settings. Intervention such as operational planning, clinical reminders, and on-site vaccination, may facilitate uptake.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126458"},"PeriodicalIF":4.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}